LifeTech Scientific Corporation will convene its annual general meeting on 28 May 2026 in Shenzhen to vote on new general mandates authorising directors to issue up to 20% of existing share capital and to repurchase up to 10%.

Key figures • Issued share capital (30 Apr 2026): 4.63 billion shares. • Proposed maximum new issuance: up to 926.34 million shares. • Proposed maximum share buy-back: up to 463.17 million shares. • Audit fee paid to Deloitte Touche Tohmatsu for FY 2025: RMB 2.70 million.

Board matters Shareholders will vote on the re-election of eight directors, including executive directors Xie Yuehui (Chairman & CEO), Liu Jianxiong (EVP & CFO), Wu Liping, Fang Yu and Feng Xiaoling; non-executive director Jiang Feng; and independent non-executive directors Zhou Luming and Chen Dongxia. Zhou, who has served for more than nine years, will be subject to a separate re-appointment resolution in line with Hong Kong listing rules.

Auditors Deloitte Touche Tohmatsu is nominated for re-appointment as external auditor for the year ending 31 December 2026, with remuneration to be set by the board.

Shareholder logistics The register of members will close from 22 May to 28 May 2026, inclusive. Share transfers must be lodged by 21 May 2026 to qualify for attendance and voting. Proxies must be submitted to Tricor Investor Services at least 48 hours before the meeting.

If approved, the new mandates will remain valid until the conclusion of the 2027 AGM, the expiry of the statutory period for holding that meeting, or revocation by shareholders, whichever occurs first.